Free Trial

Alnylam Pharmaceuticals (ALNY) News Today

Alnylam Pharmaceuticals logo
$481.67 +0.60 (+0.12%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$482.39 +0.72 (+0.15%)
As of 10/17/2025 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Why Is Alnylam Pharmaceuticals Up Today?

Alnylam Pharmaceuticals (ALNY) — The stock is trading higher today amid analyst support and momentum headlines, but sentiment is mixed because Leerink/Leerink Partnrs has cut near-term EPS estimates and issued more cautious guidance. Investors are likely reacting to the Truist price‑target lift and a fresh 52‑week high while weighing Leerink's downward revisions ahead of Alnylam's Q3 webcast.

  • Positive Sentiment: Truist raised its price target to $535 and reiterated a "buy" rating, signaling analyst conviction and ~11% implied upside from current levels — a catalyst underpinning the rally. Truist Raises Price Target to $535
  • Positive Sentiment: Technical momentum: coverage noted ALNY hit a new 52‑week high, which can attract momentum and ETF flows. ALNY Hits New 52-Week High
  • Positive Sentiment: Analysts and press are re‑assessing valuation after reports of new partnerships, pipeline progress and fresh financing — narrative that supports a higher valuation multiple if execution continues. Assessing Valuation Following New Partnerships
  • Neutral Sentiment: Alnylam scheduled a webcast to discuss Q3 2025 results — a near‑term event that will drive volatility and give clarity on revenue/guidance vs. recent analyst revisions. Q3 2025 Webcast
  • Neutral Sentiment: Coverage pieces summarizing Leerink's forecasts (FY2026 discussions) are circulating — useful for investors but not new company data. Leerink FY2026 Forecast Summary
  • Negative Sentiment: Leerink/Leerink Partnrs cut near‑term EPS estimates sharply (Q3 down from $0.38 to $0.03) and lowered FY2025 EPS (to about -$0.10), flagging weaker near‑term earnings outlook that could pressure the stock if confirmed. Leerink Lowers EPS Estimates
  • Negative Sentiment: Leerink reportedly moved to a "hold" view in coverage (coverage note highlighted by press) — a more cautious stance that can limit upside from investor flows even with positive headlines. Leerink Issues Hold

Bottom line for investors: upside today is driven by the Truist upgrade, valuation/pipeline optimism and technical strength; watch the Q3 webcast and Leerink's lowered near‑term EPS assumptions for confirmation — those items are the most likely near‑term drivers of further moves in ALNY.

Posted 1+ days agoAI Generated. May Contain Errors.

ALNY Latest News

Leerink Partnrs Brokers Lower Earnings Estimates for ALNY
Alnylam Pharma (ALNY) Gets a Hold from Leerink Partners
What is Leerink Partnrs' Forecast for ALNY FY2026 Earnings?
Leerink Partnrs Issues Negative Outlook for ALNY Earnings
Alnylam Pharma (ALNY) Gets a Hold from Morgan Stanley
RNAi: The Benefits Of Shooting The Messenger
Get Alnylam Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALNY Media Mentions By Week

ALNY Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ALNY
News Sentiment

0.73

0.48

Average
Medical
News Sentiment

ALNY News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ALNY Articles
This Week

35

23

ALNY Articles
Average Week

Get the Latest News and Ratings for ALNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


This page (NASDAQ:ALNY) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners